A Phase II Open-label Study Investigating the Efficacy, Safety and Pharmacokinetic Properties of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Oblato, Inc.
- 入组人数
- 57
- 试验地点
- 13
- 主要终点
- Incidents of Adverse Events during the subjects are taking OKN-007 with Temozolomide
研究概览
简要总结
This is a phase II open-label study investigating the efficacy, safety and pharmacokinetic(PK) properties of OKN-007 combined with temozolomide(TMZ) in patients with recurrent glioblastoma(GBM). All patients will have been previously treated with the standard-of-care treatment which includes surgical resection, radiation and chemotherapy, and in some cases treatment for recurrent disease. Patients with unequivocal recurrence (first or greater) established by MRI and meeting inclusion and exclusion criteria, will be eligible for OKN-007 treatment on this protocol.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed Glioblastoma based on histopathology or molecular profile analysis (WHO Grade IV), following primary treatment with TMZ and radiotherapy (minimum of 50 Gy) and at least two cycles of maintenance TMZ (5 days of a 28 day cycle) as first-line or second-line treatment with another treatment regimen, excluding bevacizumab.
- •Patients must have medical records available documenting O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status analysis or must have tumor tissue samples available from prior GBM surgery or open biopsy for MGMT status determination.
- •For patients with unresected recurrent tumor, unequivocal radiographic evidence of tumor progression by MRI. These patients must have at least one measurable lesion.
- •Patients with recent resection of recurrent viable tumor are eligible following post-operative MRI perfusion scan with or without measurable lesions.
- •No more than two prior lines of therapy for glioblastoma. Any second-line therapy is acceptable, excluding bevacizumab as second line.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
- •Full recovery (≤ grade 1) from the toxic effects.
- •Adequate renal, liver and bone marrow function:
- •Hemoglobin >9.0 g/dL
- •Leukocytes >3,000/mcL
- •Absolute neutrophil count >1,500/mcL
- •Platelets >100,000/mcL
- •Total bilirubin ≤ 1.5 × upper limit of normal (ULN)
- •AST (SGOT) / ALT (SGPT) ≤2.5 × ULN
- •Creatinine clearance ≥ 60 mL/min
- •Patients must be ≥18 years of age
排除标准
- •Early discontinuation of TMZ in prior line due to treatment related Adverse events (AEs).
- •Second primary malignancy expected to require treatment within a 6 month period (except adequately treated basal cell carcinoma of the skin).
- •Have received treatment within the last 28 days with a drug that has not received regulatory approval for any indication at the time of study entry.
- •Have received chemotherapeutic agents (including temozolomide) within 28 days or within 5 half-lives for non-cytotoxic agents (whichever is shorter) of study entry
- •Serious concomitant systemic disorders
- •Patients with abnormal sodium, potassium, or creatinine levels ≥ grade
- •Patients with prothrombin time/partial thromboplastin time (PT/PTT) or International normalized ratio (INR) above the ULN.
- •Inability to comply with protocol or study procedures.
- •Patients who have received bevacizumab for recurrent glioblastoma or are planning to initiate treatment with bevacizumab for tumor necrosis. (Past treatment with bevacizumab for tumor necrosis is acceptable).
- •Patients receiving or planning to initiate treatment with the tumor treating fields device (Optune®) (Optune® prior to enrollment is permitted).
研究组 & 干预措施
All patients
All patients enrolled in this study
干预措施: OKN-007 (Drug)
All patients
All patients enrolled in this study
干预措施: Temozolomide (TMZ) (Drug)
结局指标
主要结局
Incidents of Adverse Events during the subjects are taking OKN-007 with Temozolomide
时间窗: Through study completion up to 24 months
Evaluate incidents of Adverse Events during the subjects are taking OKN-007 with Temozolomide. Adverse events will be graded according to Common Terminology Criteria for Adverse Events (CTCAE, version 5.0).
Overall Survival (OS) rate
时间窗: 6 months
Proportion of subjects who are alive after six months of starting treatment. OS is defined as the time from first treatment dose until date of death due to any cause.
次要结局
- Overall Response Rate (ORR%)(24 months)
- Progression Free Survival (PFS) rate(6 months)
- Cmax of OKN-007 in blood plasma(Day 1 and Day 5 in Cycle 1 and 2 (28 Day Cycle))
- AUC of OKN-007 in blood plasma(Day 1 and Day 5 in Cycle 1 and 2 (28 Day Cycle))
- Tmax of OKN-007 in blood plasma(Day 1 and Day 5 in Cycle 1 and 2 (28 Day Cycle))
- Cmax of Temozolomide in blood plasma(Day 1 and Day 5 in Cycle 1 and 2 (28 Day Cycle))
- AUC of Temozolomide in blood plasma(Day 1 and Day 5 in Cycle 1 and 2 (28 Day Cycle))
- Tmax of Temozolomide in blood plasma(Day 1 and Day 5 in Cycle 1 and 2 (28 Day Cycle))